134 related articles for article (PubMed ID: 27781258)
1. [Research status quo and progression in targeted therapy for advanced gastric cancer].
Feng R; Zhang X; Yang S
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Oct; 19(10):1191-1196. PubMed ID: 27781258
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy in gastric cancer.
Thiel A; Ristimäki A
APMIS; 2015 May; 123(5):365-72. PubMed ID: 25706252
[TBL] [Abstract][Full Text] [Related]
3. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?
Wong H; Yau T
Oncologist; 2012; 17(3):346-58. PubMed ID: 22334453
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
6. Advanced HER2-positive gastric cancer: current and future targeted therapies.
Pazo Cid RA; Antón A
Crit Rev Oncol Hematol; 2013 Mar; 85(3):350-62. PubMed ID: 23021388
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?
Pasini F; Fraccon AP; Modena Y; Bencivenga M; Giacopuzzi S; La Russa F; Gusella M; de Manzoni G
Gastric Cancer; 2017 Jan; 20(1):31-42. PubMed ID: 27568322
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy for gastric cancer: Current status and future directions (Review).
Yuan DD; Zhu ZX; Zhang X; Liu J
Oncol Rep; 2016 Mar; 35(3):1245-54. PubMed ID: 26718131
[TBL] [Abstract][Full Text] [Related]
9. HER-2-positive breast cancer: hope beyond trastuzumab.
Bartsch R; Wenzel C; Zielinski CC; Steger GG
BioDrugs; 2007; 21(2):69-77. PubMed ID: 17402790
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives.
Roviello G; Polom K; Petrioli R; Marano L; Marrelli D; Paganini G; Savelli V; Generali D; De Franco L; Ravelli A; Roviello F
Tumour Biol; 2016 Jan; 37(1):127-40. PubMed ID: 26566626
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy in advanced gastric carcinoma: the future is beginning.
Schinzari G; Cassano A; Orlandi A; Basso M; Barone C
Curr Med Chem; 2014; 21(8):1026-38. PubMed ID: 24304282
[TBL] [Abstract][Full Text] [Related]
12. Targeting receptor tyrosine kinases in gastric cancer.
Morishita A; Gong J; Masaki T
World J Gastroenterol; 2014 Apr; 20(16):4536-45. PubMed ID: 24782606
[TBL] [Abstract][Full Text] [Related]
13. [HER2-positive breast cancer: available targeted agents and biomarkers for therapy response].
Mihály Z; Gyõrffy B
Magy Onkol; 2013 Sep; 57(3):147-56. PubMed ID: 24107820
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging targeted therapies for metastatic breast cancer.
Perez EA; Spano JP
Cancer; 2012 Jun; 118(12):3014-25. PubMed ID: 22006669
[TBL] [Abstract][Full Text] [Related]
15. Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects.
Abdel-Rahman O
Crit Rev Oncol Hematol; 2015 Jan; 93(1):18-27. PubMed ID: 24970311
[TBL] [Abstract][Full Text] [Related]
16. Metastatic gastric cancer - focus on targeted therapies.
Meza-Junco J; Sawyer MB
Biologics; 2012; 6():137-46. PubMed ID: 22807624
[TBL] [Abstract][Full Text] [Related]
17. Resistance to human epidermal growth factor receptor type 2-targeted therapies.
Thery JC; Spano JP; Azria D; Raymond E; Penault Llorca F
Eur J Cancer; 2014 Mar; 50(5):892-901. PubMed ID: 24462377
[TBL] [Abstract][Full Text] [Related]
18. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways).
Aguilar-Company J; Fernández-Ruiz M; García-Campelo R; Garrido-Castro AC; Ruiz-Camps I
Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S41-S52. PubMed ID: 29426804
[TBL] [Abstract][Full Text] [Related]
19. Renal Toxicities of Targeted Therapies.
Abbas A; Mirza MM; Ganti AK; Tendulkar K
Target Oncol; 2015 Dec; 10(4):487-99. PubMed ID: 25922090
[TBL] [Abstract][Full Text] [Related]
20. [Molecular targeting agents for advanced or recurrent gastric cancer patients].
Fuse N
Nihon Rinsho; 2012 Oct; 70(10):1819-26. PubMed ID: 23198568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
